HOME >> BIOLOGY >> NEWS
Active psoriatic arthritis patients on REMICADE achieve major clinical response in arthritis

SAN DIEGO, CALIF., NOVEMBER 13, 2005 New data, including two-year treatment duration, show a significantly higher proportion of patients with active psoriatic arthritis receiving REMICADE (infliximab) achieved and sustained a high degree of clinical improvement in arthritis, as assessed using the rheumatoid arthritis (RA) definition for "major clinical response," compared with patients receiving placebo. "Major clinical response" is defined as maintenance of a 70 percent improvement in the American College of Rheumatology score (ACR 70) for six continuous months. REMICADE maintenance therapy also resulted in the inhibition of structural damage and significant improvements in functional status and quality of life as maintained over the course of one year. Investigators will present these long-term Phase 2 and 3 study findings this week at the American College of Rheumatology 2005 Annual Scientific Meeting. REMICADE is currently indicated for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis.

"Previous study findings have shown the rapidity and therapeutic intensity of infliximab in treating the joint and skin manifestations associated with active psoriatic arthritis," said Arthur Kavanaugh, MD, Director, Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, and lead study investigator. "These data demonstrate the rapid efficacy of infliximab can be sustained over time, especially as it relates to the arthritic component of this complex disease."

An analysis of two double-blind, placebo-controlled trials, Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) and Induction and Maintenance Psoriatic Arthritis Clinical Trial 2 (IMPACT 2), followed patients for two years (98 weeks) and one year (54 weeks), respectively, and confirmed a significant, high degree of clinical responses in the arthritic component of the disease. Placebo p
'"/>

Contact: Michael Parks
215-325-4010
Centocor, Inc.
16-Nov-2005


Page: 1 2 3 4

Related biology news :

1. Active lifestyle reduces risk of invasive breast cancer
2. Active ingredient in common Chinese herb shown to reduce hypertension
3. Active inbreeding avoidance in wild capuchin monkeys
4. UD awarded $11M for osteoarthritis research and unique mentoring program for women scientists
5. Breakthrough developments in rheumatoid arthritis reported
6. University of Manchester researchers reveal clues to new genes behind rheumatoid arthritis
7. Cartilage discovery offers arthritis hope
8. Rock climbing does not increase risk of osteoarthritis
9. U-M study offers new perspective on nitric oxide signaling in rheumatoid arthritis
10. Turmeric prevents experimental rheumatoid arthritis, bone loss, University of Arizona study shows
11. Can Gleevec help patients with rheumatoid arthritis?

Post Your Comments:
(Date:7/29/2014)... has received from the National Institutes of Health ... project to support the further development of 23andMe,s ... , Specifically, the grant supports four areas ... to improve the company,s ability to identify novel ... to support the collection of a broader set ...
(Date:7/29/2014)... 1 in 100,000 people characterized by a loss of ... unknown, a new study by a team of researchers at ... and other European institutions confirms for the first time that ... July in Nature Genetics , is an important step ... sphincter in the lower esophagus opens, allowing food to enter ...
(Date:7/28/2014)... of two additional coral communities showing signs of damage from ... the 2010 spill in the Gulf of Mexico. The discovery ... of biology at Penn State University. A paper describing this ... the Gulf of Mexico will be published during the last ... the journal Proceedings of the National Academy of Sciences ...
Breaking Biology News(10 mins):23andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 3Mysterious esophagus disease is autoimmune after all 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2
(Date:7/29/2014)... Second generation biofuels are a viable solution to ... as natural gas is very cheap, this is affecting the ... valuable as they could be in comparison to natural gas. ... made it difficult for renewable energy developers to get the ... For these reasons, certain companies have shifted their focused within ...
(Date:7/29/2014)... , July 29, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, applauds the ... taking a strong position in opposition to current ... 27, 2014 publication.  The New York Times also ... this week exploring the issue called "High Time:  ...
(Date:7/29/2014)... Tenn. (PRWEB) July 29, 2014 ... in biomass feedstock supply innovation and supply chain ... proprietary feedstock management systems, Energy Grangeā„¢ and Supply ... of R&D and in-the-field testing aimed at consolidating ... offering benefits to landowners, farmers and feedstock end ...
(Date:7/29/2014)... 29, 2014 G-CON Manufacturing Inc., the ... today announced a new leadership appointment designed to drive ... and abroad. , Maik Jornitz, Chief Operating Officer ... President charged with leading the pioneering company through its ... this stage of development and look forward to providing ...
Breaking Biology Technology:Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2
Cached News: